PMID- 10193936
OWN - NLM
STAT- MEDLINE
DCOM- 19990430
LR  - 20151119
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 85
IP  - 7
DP  - 1999 Apr 1
TI  - Prospective study of the value of serum chromogranin A or serum gastrin levels in 
      the assessment of the presence, extent, or growth of gastrinomas.
PG  - 1470-83
AB  - BACKGROUND: Serum chromogranin A levels (CgA) are reported by some authors to be 
      of clinical utility for assessing the presence or absence of a pancreatic 
      endocrine tumor and tumor extent or growth. The aim of the current study was to 
      assess this finding and compare the results with those from serum gastrin 
      determinations (FSG) in a large cohort of patients with gastrinomas. METHODS: In 
      112 consecutive patients with the Zollinger-Ellison syndrome serum CgA and FSG 
      levels were measured and correlated with disease activity, extent of disease, and 
      the presence of multiple endocrine neoplasia type-1 (MEN-1) or gastric carcinoid 
      tumors. RESULTS: Serum CgA levels drawn on 2 consecutive days correlated closely 
      (P < 0.00001) as did serum gastrin levels. Serum CgA levels correlated 
      significantly with FSG levels (P < 0.00001). Serum CgA and FSG levels were 
      significantly higher in patients with active disease than in disease free 
      patients (P < 0.00001). The sensitivity for the presence of disease was higher 
      for CgA compared with FSG (92% vs. 80%; P = 0.021). However, the specificity of 
      CgA was 67%. Serum CgA levels were not significantly different in the four 
      disease categories (stable extrahepatic disease, increasing extrahepatic disease, 
      stable liver metastases, and increasing liver metastases). FSG levels were 
      significantly lower in patients with stable extrahepatic disease compared with 
      those with increasing extrahepatic disease. However, both tumor markers decreased 
      significantly with a gastrinoma resection in five patients. The presence of MEN-1 
      or a gastric carcinoid tumor did not influence the results. CONCLUSIONS: The 
      results of the current study showed that serum CgA and FSG levels both are 
      sensitive tumor markers for the detection of a gastrinoma; however, CgA levels 
      have a relatively low specificity. Neither the magnitude of the serum CgA nor 
      gastrin level correlated with tumor growth or tumor extent and therefore cannot 
      be used to determine these variables. However, in contrast to some other studies, 
      the results of the current study show that changes in serum CgA or gastrin in a 
      given patient with time are related to the tumor extent and not to gastric 
      mucosal changes due to hypergastrinemia.
FAU - Goebel, S U
AU  - Goebel SU
AD  - Digestive Diseases Branch, National Institute of Diabetes and Digestive and 
      Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-1804, 
      USA.
FAU - Serrano, J
AU  - Serrano J
FAU - Yu, F
AU  - Yu F
FAU - Gibril, F
AU  - Gibril F
FAU - Venzon, D J
AU  - Venzon DJ
FAU - Jensen, R T
AU  - Jensen RT
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CHGA protein, human)
RN  - 0 (Chromogranin A)
RN  - 0 (Chromogranins)
RN  - 0 (Gastrins)
SB  - IM
CIN - Cancer. 1999 Oct 1;86(7):1377-8. PMID: 10506728
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*blood
MH  - Carcinoid Tumor/blood
MH  - Chromogranin A
MH  - Chromogranins/*blood
MH  - Female
MH  - Gastrinoma/blood/*diagnosis/*pathology
MH  - Gastrins/*blood
MH  - Humans
MH  - Liver Neoplasms/secondary
MH  - Male
MH  - Middle Aged
MH  - Multiple Endocrine Neoplasia Type 1/blood
MH  - Prospective Studies
MH  - Sensitivity and Specificity
MH  - Stomach Neoplasms/blood
MH  - Zollinger-Ellison Syndrome/blood
EDAT- 1999/04/08 02:03
MHDA- 2000/06/20 09:00
CRDT- 1999/04/08 02:03
PHST- 1999/04/08 02:03 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1999/04/08 02:03 [entrez]
AID - 10.1002/(SICI)1097-0142(19990401)85:7<1470::AID-CNCR7>3.0.CO;2-S [pii]
PST - ppublish
SO  - Cancer. 1999 Apr 1;85(7):1470-83.